The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...

As one of the few cancers on the rise, it’s important to know the facts about endometrial cancer—especially if you are a postmenopausal woman. (Women 45 and younger are rarely diagnosed.) ...

Endometrial cancer starts in the tissue that lines your uterus. If the cancer is platinum-resistant, platinum-based chemotherapy drugs will not work well to kill it or stop it from returning after ...

The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial cancer, a recent phase 3 trial found.

The new data will help researchers train next-generation AI models that are applicable to ethnically and demographically ...

—A new study from California-based researchers reports that things may be getting worse for certain women at risk for endometrial cancer. Here’s what the research team adds to what’s known ...

Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the identification of ...

"The lack of a significant link between AmygA and LN metastasis in premenopausal women suggests that menopausal status may ...

Uterine manipulation with an intrauterine device is the surgical method used for early-stage cervical cancer. In this study, ...